Loading...
•
Jun 30, 2022
Cassava Sciences Q2 2022 Earnings Report
Announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.
Key Takeaways
Cassava Sciences reported a net loss of $19.3 million for the second quarter of 2022, with cash and cash equivalents totaling $197.2 million as of June 30, 2022. A total of over 400 patients are now enrolled in the Phase 3 program of simufilam in Alzheimer’s disease.
Over 400 patients are now enrolled in the Phase 3 program of simufilam in Alzheimer’s disease.
An open-label extension study for the Phase 3 program is expected to be initiated in the second half of 2022.
Top-line clinical results for the open-label study are expected to be announced approximately year-end 2022.
Patient enrollment for the CMS is expected to be completed in Q4 2022, with clinical results anticipated in Q3 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...